Cloacogenic Carcinoma disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: CLC003 MIFTS: 39	Cloacogenic Carcinoma Categories: Cancer diseases, Gastrointestinal diseases
Genes Tissues Related diseases Publications Pathways Drugs Expand all tables

Sources

Aliases & Classifications for Cloacogenic Carcinoma

MalaCards integrated aliases for Cloacogenic Carcinoma:

Name: Cloacogenic Carcinoma ¹² ¹⁵ ⁷⁴

Cloacogenic Anal Carcinoma ¹²

Classifications:

MalaCards categories:
Global: Cancer diseases
Anatomical: Gastrointestinal diseases

See all MalaCards categories (disease lists)

External Ids:

Disease Ontology ¹² DOID:7173

MeSH ⁴⁵ C563020

NCIt ⁵¹ C8255

SNOMED-CT ⁶⁹ 84570003

UMLS ⁷⁴ C0334273

Sources

Summaries for Cloacogenic Carcinoma

MalaCards based summary : Cloacogenic Carcinoma, also known as cloacogenic anal carcinoma, is related to rectal cloacogenic carcinoma and extraskeletal chondroma. An important gene associated with Cloacogenic Carcinoma is KERA (Keratocan), and among its related pathways/superpathways are NF-kappaB Signaling and G alpha (s) signalling events. The drugs Fluorouracil and Cisplatin have been mentioned in the context of this disorder. Affiliated tissues include thyroid, breast and prostate, and related phenotypes are cellular and craniofacial

Sources

Related Diseases for Cloacogenic Carcinoma

Diseases related to Cloacogenic Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 108)

#	Related Disease	Score	Top Affiliating Genes
1	rectal cloacogenic carcinoma	12.3
2	extraskeletal chondroma	10.4	PTH PTHLH
3	sclerosing hepatic carcinoma	10.4	PTH PTHLH
4	invasive malignant thymoma	10.4	PTH PTHLH
5	hypocalciuric hypercalcemia, familial, type iii	10.4	PTH PTHLH
6	hymenolepiasis	10.4	KRT4 KRT5
7	scleredema adultorum	10.4	POMC PTH
8	oncogenic osteomalacia	10.4	PTH PTHLH
9	breast squamous cell carcinoma	10.4	KRT5 PTHLH
10	central nervous system germ cell tumor	10.3	POMC SOX2
11	sensory organ benign neoplasm	10.3	ENO2 KRT5
12	middle ear adenoma	10.3	ENO2 KRT5
13	lymphocytic hypophysitis	10.3	ENO2 POMC
14	primitive neuroectodermal tumor of the cervix uteri	10.3	ENO2 PTPRC
15	angiomyoma	10.3	ENO2 PTHLH
16	thyroid crisis	10.3	POMC PTH
17	bronchus cancer	10.3	ENO2 POMC
18	malignant acrospiroma	10.3	CEACAM5 KRT5
19	esophageal adenosquamous carcinoma	10.3	CEACAM5 KRT5
20	uremic neuropathy	10.3	B2M PTH
21	malignant spiradenoma	10.3	CEACAM5 KRT5
22	cervical clear cell adenocarcinoma	10.3	ENO2 KRT5
23	bile duct mucoepidermoid carcinoma	10.3	CEACAM5 KRT5
24	lipoadenoma	10.2	KRT5 PTH
25	conventional fibrosarcoma	10.2	ENO2 PTPRC
26	olfactory nerve neoplasm	10.2	ENO2 POMC
27	kidney rhabdoid cancer	10.2	ENO2 PTPRC
28	endometrial small cell carcinoma	10.2	ENO2 PTPRC
29	gastric squamous cell carcinoma	10.2	ENO2 KRT5
30	epidural neoplasm	10.2	CD27 KRT5 PTPRC
31	fibrogenesis imperfecta ossium	10.2	CALCA PTH
32	liver sarcoma	10.2	CEACAM5 PTHLH
33	orbital cyst	10.2	CEACAM5 SOX2
34	tibial neuropathy	10.2	B2M POMC
35	tarsal tunnel syndrome	10.2	B2M POMC
36	malignant biphasic mesothelioma	10.2	CEACAM5 KRT5
37	tuberculous empyema	10.2	CEACAM5 POMC
38	solitary osseous plasmacytoma	10.2	B2M CD27
39	melanotic medulloblastoma	10.2	CEACAM5 ENO2
40	connective tissue benign neoplasm	10.2	ENO2 PTH
41	lymphoepithelioma-like carcinoma	10.2	ENO2 KRT5
42	corneal dystrophy, posterior amorphous	10.2	KERA PTPRC
43	ovarian lymphoma	10.2	CEACAM5 PTPRC
44	pericardial tuberculosis	10.2	CEACAM5 POMC
45	extraskeletal ewing sarcoma	10.2	ENO2 PTPRC
46	reflex sympathetic dystrophy	10.2	CALCA NPS
47	clear cell adenoma	10.1	CEACAM5 PTH PTHLH
48	rete testis adenocarcinoma	10.1	CEACAM5 ENO2
49	thymus lipoma	10.1	PTH PTPRC
50	pancreatic somatostatinoma	10.1	CALCA ENO2

Graphical network of the top 20 diseases related to Cloacogenic Carcinoma:

Sources

Symptoms & Phenotypes for Cloacogenic Carcinoma

MGI Mouse Phenotypes related to Cloacogenic Carcinoma:

⁴⁷

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	cellular	MP:0005384	9.91	B2M CD27 ENO2 PECAM1 POMC PTH
2	craniofacial	MP:0005382	9.63	ENO2 KRT4 KRT5 PTH PTHLH SOX2
3	digestive/alimentary	MP:0005381	9.5	B2M KRT4 KRT5 PECAM1 PTHLH PTPRC
4	immune system	MP:0005387	9.28	B2M CD27 KERA PECAM1 POMC PTH

Sources

Drugs & Therapeutics for Cloacogenic Carcinoma

Drugs for Cloacogenic Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 20)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Fluorouracil

Approved

Phase 3,Phase 2

51-21-8

3385

Synonyms:

1004-03-1

1-fluoro-1h-pyrimidine-2,4-dione

1upf

2,4-Dihydroxy-5-fluoropyrimidine

2,4-Dioxo-5-fluoropryimidine

2,4-Dioxo-5-fluoropyrimidine

47576_FLUKA

4921-97-5

5 Fluorouracil

5 Fluorouracil biosyn

5 FU lederle

5 FU Lederle

5 FU medac

5 HU hexal

5 HU Hexal

51-21-8

5-Faracil

5-Fluor-2,4(1H,3H)-pyrimidindion

5-Fluor-2,4(1H,3H)-pyrimidindion [Czech]

5-Fluor-2,4-dihydroxypyrimidin

5-Fluor-2,4-dihydroxypyrimidin [Czech]

5-Fluor-2,4-pyrimidindiol

5-Fluor-2,4-pyrimidindiol [Czech]

5-Fluoracil

5-Fluoracil [German]

5-Fluoracyl

5-fluoro uracil

5-fluoro-1H-pyrimidine-2,4-dione

5-Fluoro-2,4(1H,3H)-pyrimidinedione

5-Fluoro-2,4-pyrimidinedione

5-Fluoropyrimidin-2,4-diol

5-fluoropyrimidine-2,4(1H,3H)-dione

5-Fluoropyrimidine-2,4-dione

5-fluorouracil

5-Fluorouracil

5-Fluorouracil-biosyn

5-Fluoruracil

5-Fluoruracil [German]

5-Fluracil

5-Ftouracyl

5FU

5-FU

5-FU (TN)

5-FU lederle

5-FU Lederle

5-FU medac

5-HU hexal

5-HU Hexal

79108-01-3

AC-11201

AC1L1FTE

AC1Q4N2X

AccuSite

Actino-Hermal

Adrucil

Adrucil (TN)

AI3-25297

AKOS000119162

AKOS003237897

Allergan brand OF fluorouracil

Allergan Brand of Fluorouracil

Arumel

BB_NC-0576

biosyn Brand of Fluorouracil

Biosyn brand OF fluorouracil

BSPBio_002048

C07649

C4H3FN2O2

Carac

Carac (TN)

Carzonal

CCRIS 2582

CHEBI:46345

CHEMBL185

CID3385

Cinco FU

CPD000038082

CPD0-1327

CSP Brand of Fluorouracil

CSP Brand OF fluorouracil

Cytosafe

D005472

D00584

Dakota brand OF fluorouracil

Dakota Brand of Fluorouracil

Dakota, fluorouracile

Dakota, Fluorouracile

DB00544

Dermatech brand OF fluorouracil

Dermatech Brand of Fluorouracil

Dermik brand OF fluorouracil

Dermik Brand of Fluorouracil

DivK1c_000054

Effluderm

Effluderm (free base)

Efudex

Efudix

Efurix

EINECS 200-085-6

EU-0100536

F 6627

F0151

F6627_SIGMA

F8423_SIGMA

Ferrer brand OF fluorouracil

Ferrer Brand of Fluorouracil

Fiverocil

Fluoro Uracil

fluoro Uracile icn

Fluoro Uracile ICN

Fluoroblastin

Fluoroplex

Fluoroplex (TN)

fluorouracil

Fluorouracil

Fluorouracil (JP15/USP/INN)

Fluorouracil [USAN:INN:BAN:JAN]

Fluorouracil gry

Fluorouracil GRY

Fluorouracil mononitrate

Fluorouracil Mononitrate

Fluorouracil monopotassium salt

Fluorouracil Monopotassium Salt

Fluorouracil monosodium salt

Fluorouracil Monosodium Salt

Fluorouracil potassium salt

Fluorouracil Potassium Salt

Fluorouracil teva brand

Fluorouracil Teva Brand

Fluorouracile

Fluoro-uracile

Fluorouracile [DCIT]

Fluorouracile dakota

Fluorouracile Dakota

fluoro-Uracile icn

Fluoro-Uracile ICN

Fluorouracil-gry

Fluorouracil-GRY

Fluorouracilo

Fluoro-uracilo

Fluorouracilo [INN-Spanish]

fluorouracilo Ferrer far

Fluorouracilo Ferrer Far

Fluorouracilum

Fluorouracilum [INN-Latin]

Fluoruracil

Fluouracil

Flurablastin

Fluracedyl

Fluracil

Fluracilum

Fluri

Fluril

Fluro Uracil

Fluroblastin

Flurodex

Flurouracil

Flurox

FT-0082524

Ftoruracil

Gry brand OF fluorouracil

Gry Brand of Fluorouracil

haemato Brand OF fluorouracil

Haemato Brand of Fluorouracil

haemato Fu

Haemato fu

haemato-Fu

Haemato-fu

Hexal brand OF fluorouracil

Hexal Brand of Fluorouracil

HMS1920O18

HMS2090I04

HMS2091F19

HMS500C16

HSDB 3228

I07-0022

ICN brand OF fluorouracil

ICN Brand of Fluorouracil

IDI1_000054

IN1335

inhibits thymilidate synthetase

KBio1_000054

KBio2_001321

KBio2_003889

KBio2_006457

KBio3_001268

KBioGR_001253

KBioSS_001321

Kecimeton

Lopac0_000536

Lopac-F-6627

LS-153

medac Brand of Fluorouracil

Medac brand OF fluorouracil

MLS000069498

MLS002415705

MolPort-000-156-102

MolPort-003-990-447

MolPort-004-758-143

MolPort-004-758-144

MolPort-005-861-486

NCGC00015442-01

NCGC00015442-03

NCGC00015442-10

NCGC00091349-01

NCGC00091349-02

NCGC00091349-03

NCGC00091349-04

NCGC00091349-05

NCGC00091349-07

NCGC00091349-08

nchembio.90-comp3

nchembio809-comp6

NCI60_001652

Neocorp brand OF fluorouracil

Neocorp Brand of Fluorouracil

Neofluor

NINDS_000054

NSC 19893

NSC19893

NSC-19893

Onkofluor

Onkoworks brand OF fluorouracil

Onkoworks Brand of Fluorouracil

Pharmachemie brand OF fluorouracil monosodium salt

Phthoruracil

Phtoruracil

Queroplex

Ribofluor

ribosepharm Brand of Fluorouracil

Ribosepharm brand OF fluorouracil

Riemser brand OF fluorouracil

Riemser Brand of Fluorouracil

Ro 2-9757

Ro-2-9757

Roche brand OF fluorouracil

Roche Brand of Fluorouracil

S1209_Selleck

SAM002264615

SMR000038082

SPBio_000291

Spectrum_000841

SPECTRUM1500305

Spectrum2_000076

Spectrum3_000434

Spectrum4_000557

Spectrum5_000718

STK297802

T5233394

tetratogen

Teva brand OF fluorouracil

Teva Brand of Fluorouracil

Timazin

TL8006093

U 8953

U-8953

Ulup

UNII-U3P01618RT

UPCMLD-DP130

UPCMLD-DP130:001

URF

WLN: T6MVMVJ EF

ZINC00897110

Cisplatin

Approved

Phase 3,Phase 2

15663-27-1

2767 441203 84093

Synonyms:

(SP-4-1)-diamminedichloridoplatinum

(SP-4-1)-diamminedichloroplatinum

(SP-4-2)-diamminedichloridoplatinum

(SP-4-2)-diamminedichloroplatinum

Abiplatin

Biocisplatinum

Briplatin

CACP

Carboquone

CDDP

CHEBI:35852

CID441203

Cis Pt II

cis-[PtCl2(NH3)2]

cis-DDP

Cis-DDP

Cis-Diaminedichloroplatinum

cis-diamminedichloridoplatinum(II)

cis-Diamminedichloroplatinum

Cis-Diamminedichloroplatinum

cis-diamminedichloroplatinum(II)

cis-Dichlorodiammineplatinum(II)

Cismaplat

Cisplatin

Cisplatine

cisplatino

Cisplatino

Cisplatinum

Cisplatyl

Citoplationo

CPD0-1392

CPDC

CPDD

DB00515

DDP

DDPT

Diamminedichloroplatinum

EU-0100918

Lederplatin

nchembio773-comp1

Neoplatin

Peyrone's chloride

Peyrone's salt

Plastin

Platamine

Platiblastin

Platidiam

Platinex

Platinol

Platinol-AQ

Platinoxan

Platinum Ammine Chloride

Platinum Ammonium Chloride

Platinum Diamine Dichloride

Randa

trans-DDP

Trans-DDP

Trans-Diaminedichloroplatinum

trans-diamminedichloridoplatinum(II)

Trans-Diamminedichloroplatinum

Trans-Dichlorodiammine Platinum

Trans-Platinumdiammine Dichloride

Antimetabolites, Antineoplastic

Phase 3,Phase 2

Immunosuppressive Agents

Phase 3,Phase 2

Immunologic Factors

Phase 3,Phase 2

Antimetabolites

Phase 3,Phase 2

Nucleic Acid Synthesis Inhibitors

Phase 3,Phase 2

Alkylating Agents

Phase 3,Phase 2

Anti-Bacterial Agents

Phase 3,Phase 2

Mitomycins

Phase 3,Phase 2

Antibiotics, Antitubercular

Phase 3,Phase 2

Cetuximab

Approved

Phase 2

205923-56-4

56842117 2333

Synonyms:

205923-56-4

Anti EGFR

cetuximab

Cetuximab

Cétuximab

Cetuximab (genetical recombination)

Cetuximab (genetical recombination) (JAN)

Cetuximab (USAN/INN)

Cetuximabum

D03455

Erbitux

Erbitux (TN)

IMC-C225

Immunoglobulin G 1 (human-mouse monoclonal C 225 gamma 1 - chain anti-human epidermal growt factor receptor), disulfide wit human-mouse monoclonal C 225 kappa - chain, dimer

nivolumab

Approved

Phase 2

946414-94-4

Capecitabine

Approved, Investigational

Phase 2

154361-50-9

60953

Synonyms:

(1-(5-Deoxy-b-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinyl)-carbamate pentyl ester

(1-(5-Deoxy-b-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinyl)-carbamic acid pentyl ester

(1-(5-Deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinyl)-carbamate pentyl ester

(1-(5-Deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinyl)-carbamic acid pentyl ester

(1-(5-Deoxy-β-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinyl)-carbamate pentyl ester

(1-(5-Deoxy-β-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinyl)-carbamic acid pentyl ester

154361-50-9

158798-73-3

5'-Deoxy-5-fluoro-N-((pentyloxy)carbonyl)cytidine

5'-deoxy-5-fluoro-N-[(pentyloxy)carbonyl]cytidine

AC1L1U83

AC1Q4KU8

Ambap154361-50-9

C110904

C12650

C15H22FN3O6

CAPE

Capecitabin

capecitabina

Capecitabina

capecitabine

Capecitabine

CAPECITABINE

Capécitabine

Capecitabine (JAN/USAN/INN)

Capecitabine [USAN]

capecitabinum

Capecitabinum

Capecitibine

Capiibine

Carbamic acid, (1-(5-deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinyl)-, pentyl ester

Caxeta

CHEBI:31348

CHEMBL1773

CID60953

D01223

DB01101

FT-0082472

HSDB 7656

LS-59070

MolPort-005-938-254

N(4)-Pentyloxycarbonyl-5'-deoxy-5-fluorocytidine

Pentyl [1-(5-deoxy-b-D-ribofuranosyl)-5-fluoro-2-oxo-1,2-dihydropyrimidin-4-yl]carbamate

Pentyl [1-(5-deoxy-b-D-ribofuranosyl)-5-fluoro-2-oxo-1,2-dihydropyrimidin-4-yl]carbamic acid

Pentyl [1-(5-deoxy-beta-D-ribofuranosyl)-5-fluoro-2-oxo-1,2-dihydropyrimidin-4-yl]carbamate

Pentyl [1-(5-deoxy-beta-D-ribofuranosyl)-5-fluoro-2-oxo-1,2-dihydropyrimidin-4-yl]carbamic acid

Pentyl [1-(5-deoxy-β-D-ribofuranosyl)-5-fluoro-2-oxo-1,2-dihydropyrimidin-4-yl]carbamate

Pentyl [1-(5-deoxy-β-D-ribofuranosyl)-5-fluoro-2-oxo-1,2-dihydropyrimidin-4-yl]carbamic acid

Pentyl 1-(5-deoxy-b-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinecarbamate

Pentyl 1-(5-deoxy-b-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinecarbamic acid

Pentyl 1-(5-deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinecarbamate

Pentyl 1-(5-deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinecarbamic acid

pentyl 1-(5-deoxy-β-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinecarbamate

Pentyl 1-(5-deoxy-β-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinecarbamate

Pentyl 1-(5-deoxy-β-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinecarbamic acid

pentyl N-[1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-methyloxolan-2-yl]-5-fluoro-2-oxopyrimidin-4-yl]carbamate

R340

R-340

RG-340

Ro 09-1978

Ro 09-1978/000

Ro-09-1978

Ro-09-1978/000

S1156_Selleck

UNII-6804DJ8Z9U

Xabine

Xeloda

Xeloda (TN)

Xeloda, Captabin, Capecitabine

ZINC03806413

Paclitaxel

Approved, Vet_approved

Phase 2

33069-62-4

36314

Synonyms:

(2AR-(2aalpha,4b,4abeta,6b,9a(a r*,betas*),11a,12a,12balpha))-b-(benzoylamino)-a-hydroxybenzenepropanoate 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester

(2AR-(2aalpha,4b,4abeta,6b,9a(a r*,betas*),11a,12a,12balpha))-b-(benzoylamino)-a-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester

(2AR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha r*,betas*),11alpha,12alpha,12balpha))-beta-(benzoylamino)-alpha-hydroxybenzenepropanoate 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester

(2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha R*,betaS*),11alpha,12alpha,12balpha))-beta-(Benzoylamino)-alpha-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester

(2AR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha r*,betas*),11alpha,12alpha,12balpha))-beta-(benzoylamino)-alpha-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester

(2AR-(2aalpha,4β,4abeta,6β,9α(α r*,betas*),11α,12α,12balpha))-β-(benzoylamino)-α-hydroxybenzenepropanoate 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester

(2AR-(2aalpha,4β,4abeta,6β,9α(α r*,betas*),11α,12α,12balpha))-β-(benzoylamino)-α-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester

12-benzoate, 9-ester with (2R,3S)-N-benzoyl-3-phenylisoserine

157069-30-2

33069-62-4

5b,20-Epoxy-1,2-a,4,7b,10b,13a-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine

5b,20-Epoxy-1,2-a,4,7b,10b,13a-hexahydroxytax-11-en-9-one 4,10-diacetic acid 2-benzoic acid 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine

5beta,20-Epoxy-1,2-alpha,4,7beta,10beta,13alpha-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine

5beta,20-Epoxy-1,2-alpha,4,7beta,10beta,13alpha-hexahydroxytax-11-en-9-one 4,10-diacetic acid 2-benzoic acid 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine

5β,20-epoxy-1,2-α,4,7β,10β,13α-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine

5β,20-epoxy-1,2-α,4,7β,10β,13α-hexahydroxytax-11-en-9-one 4,10-diacetic acid 2-benzoic acid 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine

7 Epi taxol

7,11-Methano-1H-cyclodeca[3,4]benz[1,2-b]oxete, benzenepropanoic acid deriv.

7,11-Methano-5H-cyclodeca[3,4]benz[1,2-b]oxete,benzenepropanoic acid deriv.

7-epi-Paclitaxel

7-Epipaclitaxel

7-Epi-paclitaxel

7-epi-Taxol

7-Epitaxol

7-Epi-taxol

AB00513812

ABI 007

abi-007

ABI007

ABI-007

Abraxane

Abraxane (TN)

Abraxane I.V. Suspension

Abraxis BioScience brand of albumin-bound paclitaxel

AC1L1IOG

AC1L1VJI

AC1L9AVF

AC-675

ACon1_002231

albumin-bound paclitaxel

Ambotz33069-62-4

ANX-513

Anzatax

Asotax

BIDD:PXR0046

Bio-0076

Bio1_000362

Bio1_000851

Bio1_001340

Bio2_000416

Bio2_000896

BMS 181339-01

BMS-181339

BMS-181339-01

BPBio1_000320

BRD-A23723433-001-01-2

BRD-A28746609-001-04-0

BRD-K62008436-001-03-1

Bris taxol

Bristaxol

BSPBio_000290

BSPBio_001152

BSPBio_002614

C07394

C466458

C47H51NO14

Capxol

CCRIS 8143

CHEBI:103439

CHEBI:45863

CHEMBL100910

CHEMBL418410

CHEMBL48

CID36314

CID441276

CID4666

CID6713921

CID6915727

cMAP_000068

CPD-8718

D00491

DB01229

DHP-107

DHP-208

DivK1c_000441

DRG-0190

DTS-301

Ebetaxel

EmPAC

Epitaxol

EU-0101201

Genaxol

Genetaxyl

Genexol

Genexol-PM

HMS1362J13

HMS1568O12

HMS1792J13

HMS1922K08

HMS1990J13

HMS2090D07

HMS2093K15

HMS501G03

HSDB 6839

I06-0014

IDI1_000441

IDI1_002171

Intaxel

KBio1_000441

KBio2_000492

KBio2_002016

KBio2_002509

KBio2_003060

KBio2_004584

KBio2_005077

KBio2_005628

KBio2_007152

KBio2_007645

KBio3_000903

KBio3_000904

KBio3_001834

KBio3_002987

KBioGR_000492

KBioGR_001893

KBioGR_002509

KBioSS_000492

KBioSS_002016

KBioSS_002517

LipoPac

LMPR0104390001

Lopac0_001201

LS-31070

MBT 0206

MEGxp0_001940

Micellar Paclitaxel

Mitotax

MLS000863266

MLS001077297

MLS002154218

MLS002172439

MLS002695976

MolPort-001-742-627

MolPort-003-665-783

MolPort-003-932-365

MPI-5018

nab-paclitaxel

Nanotaxel

NCGC00024995-02

NCGC00024995-03

NCGC00024995-04

NCGC00024995-05

NCGC00024995-06

NCGC00024995-07

NCGC00164367-01

NCGC00164367-02

NCGC00164367-03

nchembio.188-comp1

nchembio.2007.34-comp9

nchembio.215-comp9

nchembio853-comp6

NCI60_000601

Neuro_000060

NINDS_000441

NK 105

Nova-12005

NP-010981

NSC 125973

NSC125973

NSC-125973

NSC358882

OAS-PAC-100

OncoGel

Onxal

Onxol

Onxol, Taxol, Nov-Onxol, Paclitaxel

P1632

Paclical

Pacligel

paclitaxel

Paclitaxel

Paclitaxel (JAN/USP)

Paclitaxel (JAN/USP/INN)

Paclitaxel (Taxol)

Paclitaxel [USAN:INN:BAN]

Paclitaxel, (4 alpha)-isomer

Paxceed

Paxene

Paxoral

Plaxicel

Praxel

Prestwick0_000155

Prestwick1_000155

Prestwick2_000155

Prestwick3_000155

Probes2_000350

QW 8184

S1150_Selleck

S-8184 Paclitaxel Injectable Emulsion

SDCCGMLS-0066823.P001

SDP-013

SMP1_000228

SMR000394086

SMR000857385

SPBio_000943

SPBio_002229

Spectrum_001536

SPECTRUM1503908

Spectrum2_000872

Spectrum3_001057

Spectrum4_001197

Spectrum5_001491

ST50306996

T 7402

T1912_SIGMA

T7191_SIGMA

T7402_SIGMA

TA1

TaxAlbin

Taxol

TAXOL

TAXOL (TN)

Taxol a

Taxol A

Taxol Konzentrat

TAXOL, 10-EPI,

Taxol, bris

Taxol.RTM. (Registered Trademark)

TXL

UNII-P88XT4IS4D

UPCMLD-DP108:001

UPCMLD-DP108:002

Vascular Wrap

weekly paclitaxel

Xorane

Yewtaxan

Carboplatin

Approved

Phase 2

41575-94-4

10339178 38904 498142

Synonyms:

(SP-4-2)-diammine[cyclobutane-1,1-dicarboxylato(2-)-kappa(2)O,O']platinum

/h1-3H2,(H,7,8)(H,9,10)

1,1-Cyclobutanedicarboxylate diammine platinum (II)

1,1-Cyclobutanedicarboxylate diammine platinum(II)

2*-1

2*1H2

41575-94-4

70903-55-8

AC-1457

AC1L8I6U

Ambap41575-94-4

azanide

Blastocarb

BSPBio_003145

C 2538

C2043

C2538_SIGMA

C6H10N2O4Pt

Carbopaltin

Carboplat

carboplatin

Carboplatin

Carboplatin (JAN/USP/INN)

Carboplatin (USAN)

Carboplatin [USAN:INN:BAN:JAN]

Carboplatine

Carboplatine [French]

Carboplatino

Carboplatino [Spanish]

Carboplatinum

Carboplatinum [Latin]

Carbosin

Carbotec

Cbdca

CBDCA

CCRIS 3404

CHEBI:31355

CHEMBL1351

CHEMBL288376

CID10339178

CID2567

CID38904

CID426756

CID498142

CID5352133

CID6398587

CID6603770

cis -Diammine[1,1-cyclobutane-dicarboxylato] platinum

cis-(1,1-cyclobutanedicarboxylato)diammineplatinum(II)

cis-(1,1-Cyclobutanedicarboxylato)diammineplatinum(II)

cis-Diamine(1,1-cyclobutanedicarboxylato)platinum(II)

cis-Diamine[1,1-cyclobutanedicarboxylato]platinum(II)

cis-Diammine(1,1-cyclobutanedicarboxylato) platinum

cis-diammine(1,1-cyclobutanedicarboxylato)platinum

cis-Diammine(1,1-cyclobutanedicarboxylato)platinum

cis-diammine(1,1-cyclobutanedicarboxylato)platinum(II)

cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II)

cis-Diammine(cyclobutanedicarboxylato)platinum II

Cyclobutane-1,1-dicarboxylate

cyclobutane-1,1-dicarboxylic acid

D01363

DB00958

Diammine(1,1-cyclobutanedicarboxylato)platinum (II)

Diammine(cyclobutane-1,1-dicarboxylato(2-)-O,O')platinum

diammine[cyclobutane-1,1-dicarboxylato(2-)-k2O1,O1]platinum

Diammine-1,1-cyclobutane dicarboxylate platinum II

DivK1c_000892

EINECS 255-446-0

Ercar

EU-0100230

HMS1921J16

HMS2090M05

HMS2092B22

HMS502M14

HSDB 6957

I14-2390

IDI1_000892

InChI=1/C6H8O4.2H2N.Pt/c7-4(8)6(5(9)10)2-1-3-6

IUPAC: Azane

JM 8

JM8

JM-8

KBio1_000892

KBio2_002009

KBio2_004577

KBio2_007145

KBio3_002645

KBioGR_000713

KBioSS_002009

Lopac0_000230

Lopac-C-2538

LS-117689

MolPort-003-665-501

MolPort-003-845-609

NCGC00015223-01

NCGC00093695-01

NCGC00094961-01

NCGC00094961-02

NCGC00094961-03

NCGC00162099-01

NCGC00162099-02

NCGC00167800-01

NCGC00178242-01

nchembio.573-comp10

nchembio773-comp2

nchembio873-comp3

Nealorin

Neocarbo

NINDS_000892

NSC 201345

NSC 241240

NSC201345

NSC241240

NSC-241240

Paraplatin

Paraplatin (TN)

Paraplatin, Carboplatin

Paraplatin-AQ

Platinum(+2) Cation

platinum(2+)

Platinum(II), (1, 1-cyclobutanedicar

Platinum, {diammine[1,1-cyclobut

Platinum, diammine(1,1-cyclobutanedicarboxylato(2-)-O,O')-, (SP-4-2)

Ribocarbo

S1215_Selleck

SPBio_000716

Spectrum_001529

SPECTRUM1502106

Spectrum2_000898

Spectrum3_001503

Spectrum4_000337

Spectrum5_001094

UNII-BG3F62OND5

Antineoplastic Agents, Immunological

Phase 2

Albumin-Bound Paclitaxel

Phase 2

Antineoplastic Agents, Phytogenic

Phase 2

Antimitotic Agents

Phase 2

Interventional clinical trials:

#	Name	Status	NCT ID	Phase	Drugs
1	Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Stage II or Stage III Anal Cancer	Unknown status	NCT00003652	Phase 3	cisplatin;fluorouracil
2	Chemotherapy Plus Radiation Therapy in Treating Patients With Stage II or Stage III Anal Cancer	Completed	NCT00003596	Phase 3	cisplatin;fluorouracil;mitomycin C
3	Radiation Therapy Plus Fluorouracil With or Without Additional Chemotherapy in Treating Patients With Primary Anal Cancer	Completed	NCT00025090	Phase 3	cisplatin;fluorouracil;mitomycin C
4	Intensity-Modulated Radiation Therapy, Fluorouracil, and Mitomycin C in Treating Patients With Invasive Anal Cancer	Completed	NCT00423293	Phase 2	fluorouracil;mitomycin C
5	Combined Modality Therapy for Patients With With HIV and Stage I, Stage II, or Stage III Anal Cancer	Completed	NCT00324415	Phase 2	cisplatin;fluorouracil
6	Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer	Recruiting	NCT03233711	Phase 2
7	Cisplatin and Fluorouracil Compared With Carboplatin and Paclitaxel in Treating Patients With Inoperable Locally Recurrent or Metastatic Anal Cancer	Active, not recruiting	NCT02560298	Phase 2	Capecitabine;Carboplatin;Cisplatin;Fluorouracil;Paclitaxel
8	Cetuximab, Cisplatin, Fluorouracil, and Radiation Therapy in Treating Patients With Anal Cancer	Active, not recruiting	NCT00316888	Phase 2	cisplatin;fluorouracil

Search NIH Clinical Center for Cloacogenic Carcinoma

Sources

Genetic Tests for Cloacogenic Carcinoma

Sources

Anatomical Context for Cloacogenic Carcinoma

MalaCards organs/tissues related to Cloacogenic Carcinoma:

⁴²

Thyroid, Breast, Prostate, Lung, Kidney, Testis, Colon

Sources

Publications for Cloacogenic Carcinoma

Articles related to Cloacogenic Carcinoma:

(show top 50) (show all 52)

#	Title	Authors	Year
1	Molecular and immunohistochemical profile of a basaloid (cloacogenic) carcinoma of the sigmoid colon: possible predictive value for clinical outcomes. ( 24584270 )	Gurzu S...Jung I	2014
2	What is the clinicopathological characteristic of cloacogenic carcinoma outside the anorectal zone? ( 21510286 )	Akbulut S	2011
3	Aggressive treatment approach for cloacogenic carcinoma of the anorectum: report from a single cancer center. ( 20689291 )	Bertani E...Andreoni B	2010
4	Basaloid (Cloacogenic) Carcinoma Mimicking Intraabdominal Abscess: Report of a Case and Review of the Literature. ( 21103283 )	Akbulut S...Ozmen CA	2009
5	Case report of long term survivor of metastatic cloacogenic carcinoma of the anal canal with chemotherapy. ( 20084726 )	Fayaz S...Motawy M	2007
6	An unusual location of cloacogenic carcinoma. ( 10096758 )	Indinnimeo M...Ghini C	1998
7	Inflammatory cutaneous metastases from cloacogenic carcinoma of the anus. ( 7633821 )	Krasnoff JB...Watsky KL	1995
8	Cloacogenic anal carcinoma presenting with humoral hypercalcemia: report of a case. ( 8640024 )	Nobusawa S...Tanaka N	1995
9	Mixed cloacogenic carcinoma of male urethra. ( 1737633 )	D?az-Cano SJ...Galera-Davidson H	1992
10	Cloacogenic carcinoma of the anal canal and associated viral lesions. An in situ hybridization study for human papilloma virus. ( 1657356 )	Aparicio-Duque R...Schinella R	1991
11	Cytokeratin polypeptide expression in a cloacogenic carcinoma and in the normal anal canal epithelium. ( 1709765 )	Levy R...Geiger B	1991
12	Transitional cloacogenic carcinoma of the female urethra treated with external irradiation and afterloading with cobalt-60. ( 2024362 )	Henriksson C...Johansson SL	1991
13	Prostatic acid phosphatase in cloacogenic carcinoma. ( 2223150 )	Fern?ndez PL...Aguilar D	1990
14	Multicentric cloacogenic carcinoma: report of a case with anogenital pruritus at presentation. ( 2229531 )	Lee KC...Muller SA	1990
15	Neurologic complications of cloacogenic carcinoma. ( 2389732 )	Garofalo M...Masdeu JC	1990
16	Small cell neuroendocrine carcinoma of the colon and rectum: clinical, histologic, and ultrastructural study and immunohistochemical comparison with cloacogenic carcinoma. ( 2434408 )	Wick MR...Weiland LH	1987
17	Simultaneous cloacogenic carcinoma in dizygotic twins. ( 3815298 )	Jovanovic L...Ezdinli EZ	1987
18	Basal cell carcinoma of the anus: clinical and pathological distinction from cloacogenic carcinoma. ( 6501831 )	White WB...Sayre JT	1984
19	Regression of pulmonary metastases from cloacogenic carcinoma after cis-platinum/5-fluorouracil treatment. ( 6539351 )	Carey RW	1984
20	An unusual type of cytokeratin filament in cells of a human cloacogenic carcinoma derived from the anorectal transition zone. ( 6179812 )	Moll R...Franke WW	1982
21	Cloacogenic carcinoma: a study of six cases and review of literature. ( 7081171 )	Khan MH...Barron J	1982
22	Perianal Paget's disease associated with cloacogenic carcinoma: report of a case. ( 6271515 )	Subbuswamy SG...Ribeiro BF	1981
23	Anal cloacogenic carcinoma: classification and clinical behavior. ( 7213001 )	Serota AI...Wilson SE	1981
24	Response of metastatic cloacogenic carcinoma to treatment with semustine. ( 7306917 )	Zimm S...Wampler GL	1981
25	Cloacogenic carcinoma. ( 7338617 )	Hertz I...Keller R	1981
26	Ectopic Cushing's syndrome in cloacogenic carcinoma of the anal canal: a case demonstrating APUD characteristics. ( 6113712 )	Bankole DO...Koonce M	1980
27	Cloacogenic carcinoma of the anus. ( 7392643 )	Slutzki S...Bogokowsky H	1980
28	Results of treatment in transitional cloacogenic carcinoma. ( 7397647 )	Svenson EW...Montague ED	1980
29	Transitional cloacogenic carcinoma of the anus and rectum: report of three cases. ( 448760 )	Scott LE...Bernard LJ	1979
30	Colonoscopic inversion in the diagnosis of cloacogenic carcinoma. ( 510887 )	Radigan JJ...Burbige EJ	1979
31	Cloacogenic carcinoma of the anorectum in homosexual men: an observation of four cases. ( 527449 )	Cooper HS...Marks G	1979
32	Cloacogenic carcinoma of the vagina. ( 761463 )	Ravden MI	1979
33	Metastatic cloacogenic carcinoma of the anus: sequential responses to adriamycin and cis-dichlorodiammineplatinum(II). ( 627000 )	Fisher WB...Critchfield CF	1978
34	Cloacogenic carcinoma. ( 666378 )	Sink JD...Seigler HF	1978
35	Histogenesis of cloacogenic carcinoma. Fine structure of anal transitional epithelium and cloacogenic carcinoma. ( 711233 )	Gillespie JJ...MacKay B	1978
36	Basosquamous (transitional cloacogenic) carcinoma of the sigmoid colon. ( 198090 )	Strate RW...Bannayan GA	1977
37	Transitional cloacogenic carcinoma of the anus. ( 832555 )	Levin SE...Kaplan L	1977
38	Cloacogenic carcinoma. ( 966304 )	Fajolu O	1976
39	Transitional-cell cloacogenic carcinoma of the anal canal: Case report. ( 1159269 )	Case TC...Gillooley JF	1975
40	Value of lymphography in detecting metastatic cloacogenic carcinoma. ( 4842493 )	Kyaw MM	1974
41	Radiation therapy in transitional cloacogenic carcinoma of the anorectal junction. ( 4718581 )	Antioniades J...Brady W	1973
42	Transitional cloacogenic carcinoma of the urethra. ( 4736268 )	Lucman L...Vadas G	1973
43	Cloacogenic carcinoma of the anal canal. ( 5013777 )	Kheir S...Gallager HS	1972
44	Cloacogenic carcinoma of the anorectal junction. Roentgenologic diagnosis. ( 5037801 )	Kyaw MM...Haines JO	1972
45	Transitional-cell cloacogenic carcinoma of the perianal region, anal canal, and rectum: report of seven cases. ( 5172130 )	Shindo K...Bacon HE	1971
46	The basal cell nature of the so-called transitional cloacogenic carcinoma of anus as revealed by electron microscopy. ( 5796777 )	Fisher ER	1969
47	Cloacogenic carcinoma. ( 5811555 )	Glickman MG...Margulis AR	1969
48	Some unusual adult male urogenital tumors with dysontogenetic features. Reports of mesonephroma, Müllerian carcinosarcoma, transitional cloacogenic carcinoma and nephroblastoma. ( 4289492 )	Robinson JJ...Jordan WP	1967
49	Transitional cloacogenic carcinoma of the anal canal. Clinicopathologic study of three hundred seventy-three cases. ( 6058180 )	Klotz RG...Souilliard DH	1967
50	Transitional cell carcinoma of the rectum (cloacogenic carcinoma). Report of a case. ( 5839639 )	Guillan RA...Zelman S	1965

Sources

Genes for Cloacogenic Carcinoma

Genes related to Cloacogenic Carcinoma (0 elite genes):

(show all 16)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence
1	KERA	Keratocan	Protein Coding	15.77	DISEASES inferred ¹⁵
2	KRT4	Keratin 4	Protein Coding	15.21	DISEASES inferred ¹⁵
3	CD27	CD27 Molecule	Protein Coding	14.12	DISEASES inferred ¹⁵
4	PTH	Parathyroid Hormone	Protein Coding	14.05	DISEASES inferred ¹⁵
5	PTHLH	Parathyroid Hormone Like Hormone	Protein Coding	13.9	DISEASES inferred ¹⁵
6	KRT5	Keratin 5	Protein Coding	13.88	DISEASES inferred ¹⁵
7	SOX2	SRY-Box 2	Protein Coding	13.71	DISEASES inferred ¹⁵
8	NPS	Neuropeptide S	Protein Coding	13.67	DISEASES inferred ¹⁵
9	POMC	Proopiomelanocortin	Protein Coding	13.67	DISEASES inferred ¹⁵
10	PTPRC	Protein Tyrosine Phosphatase Receptor Type C	Protein Coding	13.44	DISEASES inferred ¹⁵
11	ENO2	Enolase 2	Protein Coding	13.4	DISEASES inferred ¹⁵
12	PECAM1	Platelet And Endothelial Cell Adhesion Molecule 1	Protein Coding	13.35	DISEASES inferred ¹⁵
13	B2M	Beta-2-Microglobulin	Protein Coding	13.35	DISEASES inferred ¹⁵
14	CALCA	Calcitonin Related Polypeptide Alpha	Protein Coding	13.01	DISEASES inferred ¹⁵
15	ARMC10	Armadillo Repeat Containing 10	Protein Coding	6.37	DISEASES inferred ¹⁵
16	CEACAM5	Carcinoembryonic Antigen Related Cell Adhesion Molecule 5	Protein Coding	2.94	DISEASES inferred ¹⁵

Sources

Variations for Cloacogenic Carcinoma

Sources

Expression for Cloacogenic Carcinoma

Search GEO for disease gene expression data for Cloacogenic Carcinoma.

Sources

Pathways for Cloacogenic Carcinoma

Pathways related to Cloacogenic Carcinoma according to GeneCards Suite gene sharing:

#	Super pathways	Score	Top Affiliating Genes
1	NF-kappaB Signaling ⁴	11.77	B2M CEACAM5 PECAM1 PTPRC
2	G alpha (s) signalling events ⁶⁷	11.19	CALCA NPS POMC PTH PTHLH

Sources

GO Terms for Cloacogenic Carcinoma

Cellular components related to Cloacogenic Carcinoma according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	extracellular space	GO:0005615	9.8	B2M CALCA ENO2 PECAM1 POMC PTH
2	external side of plasma membrane	GO:0009897	9.46	B2M CD27 PECAM1 PTPRC
3	cell surface	GO:0009986	9.35	B2M CD27 CEACAM5 KRT4 PTPRC
4	extracellular region	GO:0005576	9.28	B2M CALCA CD27 CEACAM5 KERA NPS

Biological processes related to Cloacogenic Carcinoma according to GeneCards Suite gene sharing:

(show all 11)

#	Name	GO ID	Score	Top Affiliating Genes
1	regulation of signaling receptor activity	GO:0010469	9.8	CALCA POMC PTH PTHLH
2	cell-cell signaling	GO:0007267	9.56	CALCA POMC PTH PTHLH
3	adenylate cyclase-activating G protein-coupled receptor signaling pathway	GO:0007189	9.54	CALCA PTH PTHLH
4	response to cadmium ion	GO:0046686	9.48	B2M PTH
5	positive regulation of T cell mediated cytotoxicity	GO:0001916	9.46	B2M PTPRC
6	regulation of gene expression	GO:0010468	9.46	PTH PTHLH PTPRC SOX2
7	positive regulation of T cell differentiation	GO:0045582	9.43	CD27 PTPRC
8	negative regulation of chondrocyte differentiation	GO:0032331	9.4	PTH PTHLH
9	neuropeptide signaling pathway	GO:0007218	9.32	NPS POMC
10	cAMP metabolic process	GO:0046058	8.96	PTH PTHLH
11	leukocyte cell-cell adhesion	GO:0007159	8.8	CALCA PECAM1 PTPRC

Molecular functions related to Cloacogenic Carcinoma according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	peptide hormone receptor binding	GO:0051428	8.96	PTH PTHLH
2	hormone activity	GO:0005179	8.92	CALCA POMC PTH PTHLH

Sources

Sources for Cloacogenic Carcinoma

¹ BioSystems

² BitterDB

³ CDC

⁴ Cell Signaling Technology

⁵ ClinicalTrials

⁶ ClinVar

⁷ CNVD

⁸ Cochrane Library

⁹ Cosmic

¹⁰ dbSNP

¹¹ DGIdb

¹² Disease Ontology

¹³ diseasecard

¹⁴ DiseaseEnhancer

¹⁵ DISEASES

¹⁶ DrugBank

¹⁷ EFO

¹⁸ ExPASy

¹⁹ FDA Approved Drugs

²⁰ FMA

²¹ GeneAnalytics

²² GeneCards

²³ GeneGo (Thomson Reuters)

²⁴ GeneHancer via GeneCards

²⁵ GeneReviews

²⁶ Genetics Home Reference

²⁷ GenomeRNAi

²⁸ GEO DataSets

²⁹ GO

³⁰ GTR

³¹ HGMD

³² HMDB

³³ HPO

³⁴ ICD10

³⁵ ICD10 via Orphanet

³⁶ ICD9CM

³⁷ IUPHAR

³⁸ KEGG

³⁹ LifeMap

⁴⁰ LncRNADisease

⁴¹ LOVD

⁴² MalaCards

⁴³ MedGen

⁴⁴ MedlinePlus

⁴⁵ MeSH

⁴⁶ MESH via Orphanet

⁴⁷ MGI

⁴⁸ miR2Disease

⁴⁹ NCBI Bookshelf

⁵⁰ NCI

⁵¹ NCIt

⁵² NDF-RT

⁵³ NIH Clinical Center

⁵⁴ NIH Rare Diseases

⁵⁵ NINDS

⁵⁶ Novoseek

⁵⁷ Novus Biologicals

⁵⁸ OMIM

⁵⁹ OMIM via Orphanet

⁶⁰ Orphanet

⁶¹ PathCards

⁶² PharmGKB

⁶³ PubMed

⁶⁴ PubMed Health

⁶⁵ QIAGEN

⁶⁶ R&D Systems

⁶⁷ Reactome

⁶⁸ Sino Biological

⁶⁹ SNOMED-CT

⁷⁰ SNOMED-CT via HPO

⁷¹ SNOMED-CT via Orphanet

⁷² TGDB

⁷³ Tocris

⁷⁴ UMLS

⁷⁵ UMLS via Orphanet

⁷⁶ UniProtKB/Swiss-Prot

⁷⁷ Wikipedia